The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis

Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis

September 17, 2017 • By Linda Childers

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Histopathology of giant cell arteritis in a temporal artery.

Histopathology of giant cell arteritis in a temporal artery.
wikimedia.org

A recent study, conducted by the Vasculitis Clinical Research Consortium and funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), examined whether the addition of abatacept, a drug that affects T cell activation, to standard prednisone treatment could reduce the risk of relapse in patients with giant cell arteritis (GCA).1 Although abatacept has been approved by the FDA to treat rheumatoid and juvenile idiopathic arthritis, there had been no prior experience with its use as a treatment option for GCA.

You Might Also Like
  • Trial Data Reveals the Limitations of Steroids in Giant Cell Arteritis Therapy
  • Giant Cell Arteritis
  • Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept
Explore This Issue
September 2017
Also By This Author
  • Rheum After 5: Finding the Balance

Carol Langford, MD, MHS, of the Center for Vasculitis Care and Research at Cleveland Clinic, and the study’s lead investigator, discussed the reasons why the study of abatacept was pursued in GCA: “Abatacept inhibits T cell activation, which is thought to play a critical role in the pathogenesis of GCA,” Dr. Langford says. “Because of this mechanism, its favorable safety profile in rheumatoid arthritis and the unmet need for additional treatment options in GCA, abatacept was an interesting drug to investigate.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Nature & Treatment of GCA

According to Dr. Langford, GCA is an inflammatory disease typically seen in older adults that affects the large blood vessels, leading to a narrowing or blocking of the vessels, which interrupts blood flow. When this affects branches of the internal or external carotid artery, this can manifest with headaches, jaw or tongue claudication, scalp tenderness or cranial ischemic complications, such as vision loss, scalp infarction or strokes.

GCA can also be associated with thoracic aortic aneurysms, according to Dr. Langford, which can occur primarily or as a late manifestation of disease. The condition is commonly associated with polymyalgia rheumatica (PMR), an inflammatory disorder that causes aching and stiffness along the shoulder and hip girdle. PMR can occur as an isolated entity or as part of the clinical spectrum of GCA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Although no uniformly applied treatment protocols exist for GCA, Dr. Langford says an initial dose of prednisone equivalent to 40–60 mg/day is commonly used, with higher doses being considered for cranial ischemic complications.

Glucocorticoids relieve symptoms and, importantly, can prevent blindness, but Dr. Langford says relapses are common in GCA patients, which lead to prolonged glucocorticoid exposure.

“Relapses in GCA are a concern not only because of the potential for disease-related organ damage, but also due to the need for prolonged glucocorticoid treatment,” Dr. Langford says, adding that side effects of glucocorticoids can include infection; osteoporosis; diabetes; cataracts; glaucoma; fluid retention, causing swelling in the lower legs; high blood pressure; problems with mood, memory, behavior and other psychological effects; and weight gain, with fat deposits in the abdomen, the face and the back of the neck.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: abatacept, ACR Journal Review, American College of Rheumatology, Giant Cell Arteritis, Glucocorticoids, patient care, prednisone, relapse, Research, rheumatology, risk, Steroid, T cell, therapy, Treatment, VasculitisIssue: September 2017

You Might Also Like:
  • Trial Data Reveals the Limitations of Steroids in Giant Cell Arteritis Therapy
  • Giant Cell Arteritis
  • Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept
  • Giant Cell Arteritis Challenging to Diagnose, Manage

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)